|Day Low/High||5.46 / 5.97|
|52 Wk Low/High||5.08 / 15.47|
* The market (and money) never sleeps -- and neither do I, it appears! * Futures were schmeissed last night and early morning. "Workin' on our night moves Trying to lose the awkward teenage blues Workin' on our night moves In the summertime And oh t...
Here are my previously mentioned longs: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
In a recent analysis on cannabis I highlighted the improved credit picture for the publicly traded companies. This morning Curaleaf announced that it has expanded its recent senior secured note offering by $50 million owing to increased investor de...
* MSOS is my 'Trade of the Month' ... and for next year * Fundamentals are strong and valuations are attractive * Legislation will likely move in the right direction in 2022 * Yesterday' announcement that Curaleaf has raised $425 million in debt, th...
* My revised levels I don't want there to be any ambiguity about the size of my positions, or about my buy and short levels, as I strive for as much transparency as possible. This column is a continued commitment towards that sort of disclosure. "Wh...
Following the recent fall from grace following the dramatic spike of only two weeks ago, I am accumulating the following individual cannabis stocks - , , , , , and . I plan to make VRNOF, GTBIF and AYRWF my largest weightings. will continue to...
What caught my eye Thursday was the bullish reversal in Curaleaf Holdings and Cresco Labs during the final minutes of the trading session.
Leading advisors pick four favorite cannabis purveyors, two marijuana ETFs and one ancillary tobacco segment firm.
I see much better stock picking and trading now.
nikogeorge dougie kass • 15 minutes ago I see investments in MSOs (multi-state operators) (i.e. , , , ) as the ones that benefit while the wait for legislation grinds into existence. As they are the ones that have the state licenses, which are limit...
One group acting better is the MSO (multi-state operator) pot names.
The cannabis sector is finally turning back up after a sharp correction that started in early February.
Leading advisors offer their favorite ideas for investors looking for exposure to the growing marijuana market.
The data estimates that the U.S. cannabis market will reach $28 billion in sales by 2022.
New York became the 16th state to legalize adult use cannabis.
Much of the cannabis money is rotating back into bitcoin plays.
There are much better places an investor can put their hard-earned cash, whether they want an aggressive or a moderate name.
The companies that staked a flag in the state for the medical program were in a great position to quickly hit the ground running.
I'm focused on stock picking and continue to hunt for more sector plays.
Aurinia Pharma has some positive catalysts, and I am taking partial gains in cannabis names as they remain strong.
Aphria investors will have a larger stake in the combined company post-merger.
I am watching names like Curaleaf and the MSOS cannabis ETF, which could keep moving higher.
It has been a challenging road for these firms, but now it appears that positive things are about to happen.
Companies are adding capacity and outlets to take advantage of voters' decision this week to legalize adult-use cannabis.
The potential of legal New York adult-use cannabis sales have been estimated at $1.5 billion a year by 2023.
Cannabis investors are keenly aware of the landscape and how it could play out for the industry.
This is a very healthy market and some consolidations and pullbacks would be advantageous for trading.